{"id":"c-peg-interferon-alpha-2a-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Hemolytic anemia"},{"rate":"5-20","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/psychiatric effects"},{"rate":"20-40","effect":"Headache"},{"rate":"20-30","effect":"Nausea"},{"rate":"5-10","effect":"Thyroid dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peg-interferon alpha-2a is a long-acting form of interferon that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory effects including upregulation of MHC molecules and activation of natural killer cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, reducing HCV replication. Together, they provide synergistic antiviral activity against hepatitis C virus.","oneSentence":"Pegylated interferon alpha-2a activates innate immune responses against hepatitis C virus, while ribavirin inhibits viral replication through multiple mechanisms including nucleotide synthesis disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:13.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT02340962","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2015-05","conditions":"Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT00008463","phase":"PHASE2","title":"A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections, Hepatitis C","enrollment":132},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT00943761","phase":"PHASE2","title":"A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-23","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT00845676","phase":"PHASE4","title":"Treatment of Acute Hepatitis C Virus in HIV Co-Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-03","conditions":"Hepatitis C, Human Immunodeficiency Virus, HIV Infections","enrollment":21},{"nctId":"NCT00006164","phase":"PHASE3","title":"Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-06","conditions":"Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver","enrollment":1050},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01544920","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-30","conditions":"Hepatitis C, Chronic","enrollment":737},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT02113631","phase":"NA","title":"Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir","status":"COMPLETED","sponsor":"Louis Stokes VA Medical Center","startDate":"2011-09","conditions":"Hepatitis C, Chronic, Cirrhosis","enrollment":50},{"nctId":"NCT02107365","phase":"PHASE2","title":"Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2013-11","conditions":"Hepatitis C Virus Genotype 4 Infection","enrollment":60},{"nctId":"NCT01937728","phase":"PHASE4","title":"Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-03","conditions":"Hepatitis C","enrollment":542},{"nctId":"NCT00759200","phase":"PHASE2","title":"Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":525},{"nctId":"NCT02761629","phase":"PHASE4","title":"Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"Hepatitis C, Chronic","enrollment":180},{"nctId":"NCT02726022","phase":"","title":"A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-02","conditions":"Hepatitis C, Chronic","enrollment":114},{"nctId":"NCT01571583","phase":"PHASE3","title":"An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-02","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":74},{"nctId":"NCT01513941","phase":"PHASE3","title":"An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-04","conditions":"Chronic Hepatitis C","enrollment":163},{"nctId":"NCT01686789","phase":"PHASE4","title":"Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4","status":"COMPLETED","sponsor":"King Abdulaziz Medical City","startDate":"2011-01","conditions":"Chronic Hepatitis C Virus","enrollment":181},{"nctId":"NCT01471574","phase":"PHASE3","title":"Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C, Genotype 1","enrollment":549},{"nctId":"NCT01257204","phase":"PHASE2","title":"Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Hepatitis C Virus","enrollment":196},{"nctId":"NCT01425970","phase":"PHASE2","title":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT01125189","phase":"PHASE2","title":"Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-07","conditions":"Hepatitis C Virus","enrollment":558},{"nctId":"NCT01389323","phase":"PHASE3","title":"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Hepatitis C","enrollment":448},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01193361","phase":"PHASE2","title":"Ph IIA Study (SOC +/- NS5B)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-10","conditions":"Hepatitis C Virus","enrollment":39},{"nctId":"NCT01573351","phase":"PHASE3","title":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":398},{"nctId":"NCT01467492","phase":"PHASE4","title":"Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-01","conditions":"Hepatitis C","enrollment":121},{"nctId":"NCT00947349","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-07","conditions":"Hepatitis C, Pharmacokinetics","enrollment":22},{"nctId":"NCT01442311","phase":"NA","title":"Directly Observed Hepatitis C Treatment in Methadone Clinics","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2007-10","conditions":"Hepatitis C, Medication Adherence","enrollment":80},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01459913","phase":"PHASE3","title":"Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT00892697","phase":"PHASE2","title":"Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-05","conditions":"Hepatitis C","enrollment":15},{"nctId":"NCT01467479","phase":"PHASE3","title":"A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-12","conditions":"Hepatitis C","enrollment":185},{"nctId":"NCT01498068","phase":"PHASE3","title":"Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-01","conditions":"Genotype 1 Chronic Hepatitis C","enrollment":36},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00535847","phase":"PHASE2","title":"A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-10","conditions":"Hepatitis C","enrollment":117},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT01329978","phase":"PHASE2","title":"Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-03","conditions":"Hepatitis C, Chronic","enrollment":332},{"nctId":"NCT01188772","phase":"PHASE2","title":"Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":147},{"nctId":"NCT01054729","phase":"PHASE2","title":"Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-01","conditions":"Hepatitis C","enrollment":64},{"nctId":"NCT01289496","phase":"PHASE2","title":"Ribavirin Dose Optimization for the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2011-02","conditions":"Chronic Hepatitis C","enrollment":13},{"nctId":"NCT01384383","phase":"PHASE2","title":"GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2011-08","conditions":"Chronic Hepatitis C","enrollment":248},{"nctId":"NCT00703118","phase":"PHASE3","title":"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":663},{"nctId":"NCT01567540","phase":"PHASE1","title":"A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients","status":"TERMINATED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2013-03","conditions":"Hepatitis C","enrollment":3},{"nctId":"NCT01797848","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00800735","phase":"PHASE3","title":"A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT00623428","phase":"PHASE3","title":"A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Hepatitis C, Chronic","enrollment":235},{"nctId":"NCT01054573","phase":"PHASE3","title":"VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2010-04","conditions":"Hepatitis C, Chronic","enrollment":90},{"nctId":"NCT00977054","phase":"PHASE4","title":"Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2009-09","conditions":"Hepatitis C","enrollment":59},{"nctId":"NCT00502099","phase":"PHASE4","title":"Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","status":"COMPLETED","sponsor":"Amr Hafez","startDate":"2006-01","conditions":"Hepatitis C","enrollment":217},{"nctId":"NCT00881582","phase":"PHASE4","title":"Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients","status":"COMPLETED","sponsor":"King Abdulaziz Medical City","startDate":"2009-01","conditions":"Chronic Hepatitis C, Renal Transplant","enrollment":32},{"nctId":"NCT00910975","phase":"PHASE4","title":"Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2007-11","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":100},{"nctId":"NCT01517308","phase":"PHASE3","title":"24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C","status":"WITHDRAWN","sponsor":"Federico II University","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00122616","phase":"PHASE3","title":"Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2003-11","conditions":"HIV Infections, Hepatitis C, Chronic","enrollment":52},{"nctId":"NCT00207311","phase":"PHASE4","title":"Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2005-08","conditions":"Fatty Liver, Hepatitis C","enrollment":30},{"nctId":"NCT01273948","phase":"PHASE1, PHASE2","title":"Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Peregrine Pharmaceuticals","startDate":"2011-01","conditions":"Hepatitis C","enrollment":66},{"nctId":"NCT00192569","phase":"PHASE4","title":"Australian Trial in Acute Hepatitis C","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-07","conditions":"Hepatitis C","enrollment":167},{"nctId":"NCT01272310","phase":"PHASE1, PHASE2","title":"Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2011-01","conditions":"Chronic Hepatitis C","enrollment":36},{"nctId":"NCT01178996","phase":"PHASE3","title":"Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":552},{"nctId":"NCT00395421","phase":"PHASE2","title":"Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Chronic Hepatitis C","enrollment":114},{"nctId":"NCT00887081","phase":"PHASE4","title":"Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies","status":"UNKNOWN","sponsor":"Azienda Ospedaliera V. Cervello","startDate":"2009-01","conditions":"Hemoglobinopathies","enrollment":150},{"nctId":"NCT00543244","phase":"","title":"Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2006-01","conditions":"Chronic Hepatitis C","enrollment":300},{"nctId":"NCT00575627","phase":"PHASE4","title":"Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2007-09","conditions":"Chronic Hepatitis C","enrollment":150},{"nctId":"NCT00629967","phase":"PHASE4","title":"A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2005-04","conditions":"Chronic Hepatitis C, Genotype","enrollment":200},{"nctId":"NCT00088504","phase":"PHASE2","title":"Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2004-07","conditions":"Hepatitis C, Hepatitis","enrollment":315},{"nctId":"NCT00148863","phase":"PHASE2","title":"Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2004-06","conditions":"Hepatitis C, Chronic","enrollment":65},{"nctId":"NCT00221624","phase":"PHASE3","title":"Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2001-11","conditions":"HCV Infection, Hepatitis C, Chronic","enrollment":131},{"nctId":"NCT00221650","phase":"PHASE2","title":"Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2002-04","conditions":"HIV Infections, Hepatitis C, Chronic, Treatment Failure","enrollment":17},{"nctId":"NCT00158496","phase":"PHASE3","title":"Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-08","conditions":"Chronic Hepatitis C","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys, Robatrol"],"phase":"marketed","status":"active","brandName":"C: Peg-interferon alpha-2a & Ribavirin","genericName":"C: Peg-interferon alpha-2a & Ribavirin","companyName":"Kaohsiung Medical University Chung-Ho Memorial Hospital","companyId":"kaohsiung-medical-university-chung-ho-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha-2a activates innate immune responses against hepatitis C virus, while ribavirin inhibits viral replication through multiple mechanisms including nucleotide synthesis disruption. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}